Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest CD135 Stories

2013-12-03 16:25:12

Company to Hold Conference Call and Webcast at 9:00 am ET, Wednesday, December 4, 2013 SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead...

2013-11-19 23:04:55

Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017. London (PRWEB) November 19, 2013 OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 Summary Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a...

2013-11-07 16:31:26

Company Announces Four Oral Presentations and Two Posters Highlighting Quizartinib To Be Presented At The 55th Meeting Of The American Society Of Hematology (ASH) SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013. The company will host a...

2013-11-07 16:30:46

- Pacritinib Phase 2 Analysis of Myelofibrosis Patients with Thrombocytopenia (Low Platelets) Accepted for Oral Presentation - SEATTLE, Nov. 7, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, a novel, oral JAK2/FLT3 inhibitor, and tosedostat, an aminopeptidase inhibitor, at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2013 in New...

2013-09-19 08:28:11

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its...

2013-08-19 23:18:19

“OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” is the new market research report added to ReportsnReports.com store. Acute Myeloid Leukemia (AML) therapeutics market to $430.7m in 2017, at a CAGR of 23.3%. Dallas, Texas (PRWEB) August 19, 2013 Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a...

2013-08-15 23:20:42

"OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017" – this new report says the main driver of growth in the global Acute Myeloid Leukemia market will be the uptake of premium-priced pipeline agents. Dallas, TX (PRWEB) August 15, 2013 Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and...

2013-08-13 16:26:07

- Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO, Aug. 13, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial...

2013-07-03 16:22:44

SAN DIEGO, July 3, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at the 8(th) Annual JMP Securities Healthcare Conference. Mr. Martino's presentation is scheduled to take place at 9:30 a.m. EDT on Wednesday, July 10, at the St. Regis New York. A live webcast of the presentation will be accessible in the investors section of the company's website, www.ambitbio.com,...

2013-07-03 04:20:34

SEATTLE, July 3, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013. The article reviews the preclinical pharmacology and pharmacokinetics in addition to the safety and efficacy results from the Phase 1 and 2 clinical studies of...